Eli Lilly Drug Retatrutide Shows Weight Loss in Type 2 Diabetes Trial

Why it matters locally: While not directly impacting Alaska's core industries, the availability of new, effective treatments for Type 2 diabetes, such as retatrutide, could significantly benefit the state's population by improving public health outcomes and potentially reducing healthcare costs associated with managing the condition.

Eli Lilly's experimental drug retatrutide led to significant weight loss among individuals with Type 2 diabetes. Participants in a late-stage clinical trial lost up to 60 pounds, which represented approximately 23% of their body weight. Researchers published the findings from the study in The Lancet on Tuesday. The results detail the effects of retatrutide, a GLP-1 receptor agonist, in individuals diagnosed with Type 2 diabetes.